» Articles » PMID: 6502174

The Treatment of Severe Dystonia in Children and Adults

Overview
Date 1984 Nov 1
PMID 6502174
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty-three children (aged less than 18 years) and 17 adults with severe widespread dystonia were treated with high doses of benzhexol (up to 130 mg daily introduced slowly over many weeks). Children tolerated higher doses (median 30 mg/day) than adults (median 20 mg/day). 52% of the children gained useful benefit, many (43%) without unwanted side effects. Such an approach was less successful in adults; 41% gained benefit, but only 35% had no side effects. Twelve adults with severe axial dystonia, and two children with life-threatening generalised dystonia were treated with a combination of a low constant dose of tetrabenazine to which were added pimozide and benzhexol as necessary. The dose of tetrabenazine was aimed at 75 mg daily; pimozide was increased (6 to 25 mg/day) until the dystonia was relieved or Parkinsonism and other side-effects prevented further increments; if necessary benzhexol (6 to 30 mg/day) then was added to control side-effects and to provide additional benefit. 75% of the adults with severe axial dystonia, and one of the two children with life threatening generalised dystonia gained useful benefit from this regime. It is concluded that high dose benzhexol is the present first treatment of choice for children with severe dystonia, and is worth a try in adults but with less expectation of success. When benzhexol treatment alone fails in adults with severe disabling axial dystonia, or in children with life-threatening generalised dystonia, combined therapy with tetrabenazine, pimozide and benzhexol may give valuable symptomatic relief.

Citing Articles

Development and Characterization of Trihexyphenidyl Orodispersible Minitablets: A Challenge to Fill the Therapeutic Gap in Neuropediatrics.

Olivera C, Boscolo O, Dobrecky C, Ortega C, Favier L, Cianchino V Pharmaceutics. 2025; 17(1).

PMID: 39861657 PMC: 11769368. DOI: 10.3390/pharmaceutics17010005.


Haloperidol in Managing DYT-TOR1A Dystonia: Unveiling a Dramatic Therapeutic Response.

Katragadda P, Holla V, Kamble N, Yadav R, Pal P J Mov Disord. 2024; 17(3):342-344.

PMID: 38589017 PMC: 11300396. DOI: 10.14802/jmd.24029.


Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact.

Jankovic J, Tsui J, Brin M Medicine (Baltimore). 2023; 102(S1):e32403.

PMID: 37499081 PMC: 10374188. DOI: 10.1097/MD.0000000000032403.


Clinical spectrum and management of dystonia in patients with Japanese encephalitis: A systematic review.

Aryal R, Shrestha S, Homagain S, Chhetri S, Shrestha K, Kharel S Brain Behav. 2022; 12(2):e2496.

PMID: 35025122 PMC: 8865161. DOI: 10.1002/brb3.2496.


Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Bledsoe I, Viser A, San Luciano M Neurotherapeutics. 2020; 17(4):1622-1644.

PMID: 33095402 PMC: 7851280. DOI: 10.1007/s13311-020-00944-0.


References
1.
Fog R, Pakkenberg H . Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes. Acta Neurol Scand. 1970; 46(2):249-51. DOI: 10.1111/j.1600-0404.1970.tb05621.x. View

2.
Swash M, Roberts A, Zakko H, HEATHFIELD K . Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry. 1972; 35(2):186-91. PMC: 494034. DOI: 10.1136/jnnp.35.2.186. View

3.
Crow T . An analysis of the learning deficit following hyoscine administration to man. Br J Pharmacol. 1973; 49(2):322-7. PMC: 1776392. DOI: 10.1111/j.1476-5381.1973.tb08379.x. View

4.
Pinder R, Brogden R, Swayer R, Speight T, Spencer R, Avery G . Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs. 1976; 12(1):1-40. DOI: 10.2165/00003495-197612010-00001. View

5.
Lane J, Smith J, SHEA P, McBride W . Neurochemical changes following the administration of depleters of biogenic monoamines. Life Sci. 1976; 19(11):1663-7. DOI: 10.1016/0024-3205(76)90071-0. View